Live Birth in Woman With Premature Ovarian Insufficiency Receiving Ovarian Administration of Platelet-Rich Plasma (PRP) in Combination With Gonadotropin: A Case Report

The conception rates among women with premature ovarian insufficiency (POI) remain extremely low. To achieve a successful pregnancy, most of these women have to receive donor oocytes through IVF treatment. Ovarian administration of platelet-rich plasma (PRP) has been recently applied to enhance the ovulatory function in women with poor ovarian response. However, no live birth has been reported for this application in patients with POI. In this study, we present a 37-year-old woman with POI who had secondary amenorrhea for 6 months. The clinical manifestations and evaluation of this women with a diminished ovarian function were an undetectable serum level of AMH (<0.02 ng/mL) and an elevated serum level of FSH (63.65 mIU/mL). A single dose of autologous PRP (extracted from 40 mL of peripheral blood) in combination with gonadotropin (150IU rFSH/75 IU rLH) was directly injected into the stroma of bilateral ovaries via vaginal sonographic guidance. Following the treatment, this patient received controlled ovarian stimulation and IVF during the successive months. Following embryo culture, three cleavage-stage embryos were transferred, leading to a successful pregnancy, which later resulted in the live birth of twins. This case report provides one example of alternative therapy that allows POI patients to use autologous oocytes in IVF treatment.

[1]  V. Harris,et al.  Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review. , 2019, Reproductive biomedicine online.

[2]  M. Koutsilieris,et al.  Autologous Platelet-Rich Plasma Treatment Enables Pregnancy for a Woman in Premature Menopause , 2018, Journal of clinical medicine.

[3]  M. Hammar,et al.  The prevalence of primary ovarian insufficiency in Sweden; a national register study , 2018, BMC Women's Health.

[4]  F. Albuz,et al.  Low Gonadotropin Dosage Reduces Aneuploidy in Human Preimplantation Embryos: First Clinical Study in a UAE Population. , 2018, Genetic testing and molecular biomarkers.

[5]  M. Koutsilieris,et al.  A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients , 2018, Gynecologic and Obstetric Investigation.

[6]  Yue-ting Zhu,et al.  Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women , 2018, Human reproduction.

[7]  G. Muschler,et al.  Variability in the Preparation, Reporting, and Use of Bone Marrow Aspirate Concentrate in Musculoskeletal Disorders: A Systematic Review of the Clinical Orthopaedic Literature , 2018, The Journal of bone and joint surgery. American volume.

[8]  G. Palermo,et al.  First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[9]  K. Ivani,et al.  High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer , 2017, Human reproduction.

[10]  G. Muschler,et al.  A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature , 2017, The Journal of bone and joint surgery. American volume.

[11]  M. Akhondi,et al.  Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. , 2017, Reproductive biomedicine online.

[12]  B. Fauser,et al.  Ovarian stimulation protocols for IVF: is more better than less? , 2017, Reproductive biomedicine online.

[13]  M. Polak,et al.  Long‐term outcome of ovarian function in women with intermittent premature ovarian insufficiency , 2017, Clinical endocrinology.

[14]  R. Cífková,et al.  ESHRE Guideline: management of women with premature ovarian insufficiency. , 2016, Human Reproduction.

[15]  Trine Høyer Rose,et al.  Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending Doses , 2016, Drugs in R&D.

[16]  Yuan Cheng,et al.  Intraovarian control of early folliculogenesis. , 2015, Endocrine reviews.

[17]  R. Dhurat,et al.  Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective , 2014, Journal of cutaneous and aesthetic surgery.

[18]  Liying Yan,et al.  Basic fibroblast growth factor promotes the development of human ovarian early follicles during growth in vitro. , 2014, Human reproduction.

[19]  Y. Morimoto,et al.  Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment , 2013, Proceedings of the National Academy of Sciences.

[20]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[21]  J. Golmard,et al.  Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. , 2011, The Journal of clinical endocrinology and metabolism.

[22]  Chao-Chin Hsu,et al.  Abdominal mesotherapy injection extended the absorption of follicle-stimulating hormone. , 2011, Fertility and sterility.

[23]  A. Shelling Premature ovarian failure. , 2010, Reproduction.

[24]  Shu Liu,et al.  Activation of dormant ovarian follicles to generate mature eggs , 2010, Proceedings of the National Academy of Sciences.

[25]  A. Gougeon Human ovarian follicular development: from activation of resting follicles to preovulatory maturation. , 2010, Annales d'endocrinologie.

[26]  Chao-Chin Hsu,et al.  The absorption and uptake of recombinant human follicle-stimulating hormone through vaginal subcutaneous injections - a pharmacokinetic study , 2009, Reproductive biology and endocrinology : RB&E.

[27]  S. Wang,et al.  Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment. , 2008, Reproductive biomedicine online.

[28]  David Handelsman,et al.  Follicle-stimulating hormone increases primordial follicle reserve in mature female hypogonadal mice. , 2006, The Journal of endocrinology.

[29]  S. Hawes,et al.  Development of spare human preimplantation embryos in vitro: An analysis of the correlations among gross morphology, cleavage rates, and development to the blastocyst , 1989, Journal of in Vitro Fertilization and Embryo Transfer.

[30]  A. Munafo,et al.  The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women. , 1998, British journal of clinical pharmacology.

[31]  K. Oktay,et al.  Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. , 1997, The Journal of clinical endocrinology and metabolism.

[32]  Rw Rebar,et al.  Clinical features of young women with hypergonadotropic amenorrhea , 1990, Fertility and sterility.

[33]  J. Annegers,et al.  Incidence of Premature Ovarian Failure , 1986, Obstetrics and gynecology.